ABBVie (NYSE: ABBV) today announced it will present data from its migraine portfolio at the 2022 American Headache Society (AHS) Annual Scientific Meeting to be held in Denver June 9-12 . A total of 29 abstracts, including two oral presentations and one late-breaker presentation, will cover a wide range of studies across ABBVie’s migraine portfolio, and highlight the company’s newest migraine treatment, atogepant (QULIPTA).
“As the only pharmaceutical company that offers three products that span the spectrum of migraine treatment, which include preventive therapies for chronic and episodic migraine and an acute treatment for migraine attacks, AbbVie is pleased to present new data across its migraine portfolio,” said Michael Gold , M.D., therapeutic area head, neuroscience development, AbbVie. “We continue to research potential new indications that may help more people living with this debilitating disease. Presenting robust data from our migraine portfolio demonstrates our commitment to people living with migraine and our goal of preserving personhood.”
Researchers will present results from multiple migraine studies, including a late-breaker poster presentation about the Phase 3 PROGRESS trial investigating the use of atogepant for preventive treatment of chronic migraine. Data from this study will support a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration for the expanded use of atogepant to include the preventive treatment of chronic migraine, potentially building on the current indication for the preventive treatment of episodic migraine. This research will support regulatory submissions globally as well.
Data also will be presented on ubrogepant (UBRELVY ® ) for acute treatment of migraine and onabotulinumtoxinA (BOTOX ® ) for the preventive treatment of chronic migraine. In addition, results from the Combining UbRogepAnt and Preventives for MiGrainE (COURAGE) study evaluating the real-world effectiveness of ubrogepant for the acute treatment of migraine when used in patients receiving onabotulinumtoxinA for the preventive treatment of chronic migraine will be presented.